

Women’s and Reproductive Health Guidelines Update Committee Meeting 42

Date: 3 November 2023

Location: Virtual via Microsoft Teams

Minutes: Confirmed

Committee members present:	
Sarah Fishburn (Chair)	Present for notes 1 – 6
Maggie Blott (Topic Advisor)	Present for notes 1 – 6
Lucy O’Malley	Present for notes 1 – 6
Sarah Griffiths	Present for notes 1 – 6
Cornelia Wiesender	Present for notes 1 – 6
Chimwemwe Kalumbi	Present for notes 1 – 6
Sophie McAllister	Present for notes 1 – 5
Frances Rivers	Present for notes 1 – 6
Sophie House	Present for notes 1 – 6
Aung Soe	Present for notes 1 – 6
Tim Watts	Present for notes 1 – 6
Alena Chong	Present for notes 1 – 6
Bryony Kendall	Present for notes 1 – 6

In attendance:		
Hilary Eadon	NICE Guideline Lead	Present for notes 1 – 6
Hayley Shaw	NICE Project Manager	Present for notes 1 – 6
Sharangini Rajesh	NICE Senior Technical Analyst	Present for notes 1 – 6
Agnesa Mehmeti	NICE Technical Analyst	Present for notes 1 – 6
Rebecca Blackburn	NICE Technical Analyst	Present for notes 1 – 6
Aye Paing	NICE Technical Analyst	Present for notes 1 – 6
Paul Jacklin	NICE Senior Health Economist	Present for notes 1 – 6
Ayisha Ashmore	NICE Clinical Fellow	Present for notes 4 – 6
Clifford Middleton	NICE Guideline Commissioning Manager	Present for notes 1 – 6
Gareth Haman	NICE Senior Medical Editor	Present for notes 1 – 6
Suzie Panek	NICE Finance Analyst	Present for notes 1 – 6

Apologies:	
Maria Clark	Lay member
Ashifa Trivedi	Pharmacist
Qudsia Malik	NICE Senior Technical Analyst
Stephanie Arnold	NICE Information Scientist
Benjamin Gregory	NICE Business Analyst

1. Welcome and objectives for the meeting.

The Chair welcomed the committee to the 42nd Women’s and Reproductive Health Suite committee meeting.

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives for the meeting, which included discussing clinical and economic evidence for T&T1 (progesterone in preventing spontaneous preterm birth in twin and triplet pregnancy).

2. Confirmation of matter under discussion, and declarations of interest

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was twin and triplet pregnancy.

The Chair asked everyone to verbally declare any interests that have arisen since the last meeting. No new interests were declared.

3. Minutes of last meeting

The Chair asked the committee to confirm the minutes of the last meeting, and the committee confirmed that no changes were required.

4. Presentations

The Chair introduced Aye Paing, Technical Analyst, who presented the clinical evidence for T&T1:

What is the clinical and cost-effectiveness of progesterone in preventing spontaneous preterm birth in twin and triplet pregnancy?

The Chair introduced Paul Jacklin, Senior Health Economist, who presented the health economic model for T&T1: What is the clinical and cost-effectiveness of progesterone in preventing spontaneous preterm birth in twin and triplet pregnancy?

5. Questions and discussions

The committee discussed the clinical and health economic evidence for T&T1 and drafted

recommendations whilst considering the impact of these recommendations on practice.

6. Any other business

The meeting was closed at 15:35

Date of next meeting:

- **GC43 – Monday 27th November 2023 – obstetric committee and endometriosis committee**
- **GC44 – Wednesday 13th December 2023 – obstetric committee**

Location of next meeting: Virtual via Microsoft Teams